Johan Wedell-Wedellsborg - Jun 8, 2023 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
Director
Signature
/s/ Sune Reinholth Nyland, Attorney-in-Fact for Johan Wedell-Wedellsborg
Stock symbol
YMAB
Transactions as of
Jun 8, 2023
Transactions value $
$0
Form type
4
Date filed
6/9/2023, 06:04 PM
Previous filing
May 17, 2023
Next filing
Nov 29, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Award $0 +2.33K $0.00 2.33K Jun 8, 2023 Direct F1
holding YMAB Common Stock 4.28M Jun 8, 2023 By WG Biotech ApS F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Award $0 +14K $0.00 14K Jun 8, 2023 Common stock 14K $8.13 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockeholders held in 2024, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on the vesting date.
F2 Reporting Person is the majority owner of WG Biotech ApS and as such has sole voting and investment power with respect to such shares.
F3 Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F4 The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on each vesting date and are exercisable immediately upon vesting.